08 July 2022
: Case report
[In Press] Unusual Case of Painful Glossitis and Xerostomia Following Vaccination with Pfizer-BioNTech SARS-CoV-2 (BNT162b2)
Unusual clinical course, Challenging differential diagnosis, Unexpected drug reaction
Elina Tan1DEF, Sam Salman231ABDEFDOI: 10.12659/AJCR.937212
Am J Case Rep In Press; DOI: 10.12659/AJCR.937212
Available online: 2022-07-08, In Press, Corrected Proof
Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule
Abstract
BACKGROUND
Adverse events following immunization (AEFIs) remain under recognized, particularly when the symptoms experienced are uncommon and mimic natural disease. In the context of the worldwide effort to provide protection against SARS-CoV-2 using multiple doses of vaccination and with the availability of multiple vaccines, the early recognition and prompt treatment of AEFIs has increased importance, as does the ability to carefully select an alternative after an AEFI occurs.
CASE REPORT
A 60-year-old woman presented for clinical immunology review with a 9-month history of glossitis and xerostomia. Onset of symptoms occurred following her first vaccination with a COVID-19 vaccine (BNT162b2). After partial interval improvement, her symptoms progressively worsened after a second vaccination and third booster vaccination with BNT162b2. While undergoing reviews from multiple specialists for possible underlying connective tissue disease, and with other causes of her symptoms being excluded, the patient’s symptoms progressed, with worsening tongue swelling with new fissuring and xerostomia. The patient experienced an unintentional weight loss of 8 kg due to oral discomfort. It was only after this time that an AEFI was considered the cause of her presentation, after all other diagnostic considerations were considered unlikely. Targeted, symptomatic, localized treatment with topical oral corticosteroids was initiated, followed by a gradual tapering regimen, with excellent response.
CONCLUSIONS
This case highlights the need to consider AEFIs early in the differential diagnosis of unusual presentations and the importance of considering a trial of targeted symptomatic treatment for patients, even if diagnostic uncertainty remains.
Keywords: Glossitis; mRNA Vaccine; BNT162 Vaccine; COVID-19 Vaccine
SARS-CoV-2/COVID-19
11 August 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936496
09 August 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937505
29 July 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937105
08 July 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937212
In Press
12 Aug 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936915
11 Aug 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.937139
11 Aug 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.936496
11 Aug 2022 : Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.935207
Most Viewed Current Articles
13 Jul 2022 : Case report
DOI :10.12659/AJCR.936441
Am J Case Rep 2022; 23:e936441
23 Feb 2022 : Case report
DOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250
06 Dec 2021 : Case report
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
17 Feb 2022 : Case report
DOI :10.12659/AJCR.934399
Am J Case Rep 2022; 23:e934399